CAMBRIDGE, England, Oct. 4, 2006 - Biotica Technology Ltd. a private UK biotechnology company, today announced the signing of an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE). This alliance is focused on the discovery, development and commercialization of novel rapamycin analogs that target diseases in multiple therapeutic areas.
